APA (7th ed.) Citation

Rogers, K. A., Thompson, P. A., Allan, J. N., Coleman, M., Sharman, J. P., Cheson, B. D., . . . Kipps, T. J. (2021). Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica (Roma), 106(9), 2364-2373. https://doi.org/10.3324/haematol.2020.272500

Chicago Style (17th ed.) Citation

Rogers, Kerry A., et al. "Phase II Study of Acalabrutinib in Ibrutinib-intolerant Patients with Relapsed/refractory Chronic Lymphocytic Leukemia." Haematologica (Roma) 106, no. 9 (2021): 2364-2373. https://doi.org/10.3324/haematol.2020.272500.

MLA (9th ed.) Citation

Rogers, Kerry A., et al. "Phase II Study of Acalabrutinib in Ibrutinib-intolerant Patients with Relapsed/refractory Chronic Lymphocytic Leukemia." Haematologica (Roma), vol. 106, no. 9, 2021, pp. 2364-2373, https://doi.org/10.3324/haematol.2020.272500.